Margaret Gatti-Mays, Deputy Director of Division of Medical Oncology Section Chief, Breast Medical Oncology Associate Professor at The Ohio State University, shared a post on LinkedIn:
“Always fun hosting a Tumor Board Tuesday session!
Tonight we discussed the rapidly expanding landscape of 2L ER+/HER2- mBC TBT.
Take home points:
- Liquid biopsy recommended at progression on 1L to screen for mutations
- 2L options have mPFS 5-11 months, some with OS benefit
- Optimal sequence unknown at this time, likely depends in part on patient factors
- Many SOC options for 2L metastatic ER+ breast cancer with my summary below Options Are Good.”
More posts featuring Margaret Gatti-Mays on OncoDaily.